Search Results

7 results

  1. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 17

    Evaluation of reduction in exposure to selected cigarette smoke constituents after switching to novel tobacco vapor product (NTV) use during a five-day confinement study in Japan

    TAKESHIGE Y.; YUKI D.; NAKAYA K.; FUTAMURA Y.
    Japan Tobacco Inc., Scientific Product Assessment Center, Yokohama, Kanagawa, Japan
    We recently developed a novel tobacco vapor product (NTV) that comprises a battery, a cartridge with a heater and nicotine-free liquid, and a tobacco capsule filled with tobacco blend. Vapor containing nicotine and flavor is produced by aerosol from the ...
  2. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 18

    Evaluation of subjective effects and product use patterns of novel tobacco vapor product (NTV) use during a five-day confinement study in Japan

    NISHIHARA D.; YUKI D.; NAKAYA K.; TAKESHIGE Y.; FUTAMURA Y.
    Japan Tobacco Inc., Scientific Product Assessment Center, Yokohama, Kanagawa, Japan
    Some authorities have highlighted information relating to the abuse liability of tobacco products as key in reaching regulatory decisions. Although abuse liability should be assessed with multiple factors, one of the essential elements is the subjective ...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, ST 27

    Pharmacokinetics of nicotine following the controlled use of a prototype novel tobacco vapour product

    YUKI D.(1,2); SAKAGUCHI C.(1); KIKUCHI A.(1); FUTAMURA Y.(1)
    (1) Japan Tobacco Inc., R&D Group, Scientific Product Assessment Center, Yokohama, Kanagawa, Japan; (2) JT International S.A., Scientific & Regulatory Affairs, Geneva, Switzerland
    The objective of this clinical study was to investigate the pharmacokinetics of nicotine following the use of a prototype novel tobacco vapour (PNTV) product in comparison to a conventional cigarette (CC1). The study was conducted in Japanese healthy ...
  4. CORESTA Congress, Berlin, 2016, Smoke Science/Product Technology Groups, ST 23

    Pharmacokinetics of nicotine following single controlled use of a new type of tobacco: heated tobacco product

    GILES L.(1); YUKI D.(2); SHERWOOD N.(3); GRAFF D.W.(4); NEWLAND K.(4)
    (1) JT International SA, Ballymena, Co. Antrim, U.K.; (2) Japan Tobacco Inc., Yokohama, Kanagawa, Japan; (3) Neil Sherwood Consulting, Commugny, Switzerland; (4) Celerion, Lincoln, NE, U.S.A.
    Nicotine is one of the most characteristic compounds contained in any type of tobacco product including cigarettes. Previous studies have reported that different types of tobacco products display differences in nicotine pharmacokinetics. NHTP is a new ...
  5. CORESTA Congress, Berlin, 2016, Smoke Science/Product Technology Groups, STPOST 38

    The retention of nicotine from a new type of heated tobacco product in human respiratory tracts

    SUZUKI T.; YUKI D.; KITAGAWA M.; SHIBATA T.
    Japan Tobacco Inc., R&D Group, Scientific Product Assessment Center, Yokohama, Kanagawa, Japan
    Nicotine is the major alkaloid in tobacco leaf and therefore present in tobacco products. Previous studies suggest that absorption sites of nicotine in human respiratory tracts affect nicotine pharmacokinetics. This study investigated the retention of ...
  6. CORESTA Meeting, Smoke Science/Product Technology, 2013, Seville, ST 37

    Good relationship between saliva cotinine kinetics and plasma cotinine kinetics after smoking one cigarette

    YUKI D.; KIKUCHI A.; MIURA N.; KAKEHI A.; ONOZAWA M.
    Japan Tobacco Inc., R&D Group, Product Science Division, Yokohama, Kanagawa, Japan
    This study investigated the relationship between plasma and saliva cotinine kinetics after smoking one cigarette and the relationship between cotinine kinetics and estimated nicotine intake, which was calculated as mouth level exposure (MLE) of nicotine, ...
  7. CORESTA Congress, Sapporo, 2012, Smoke Science/Product Technology Groups, SSPT 18

    Estimation of mouth level smoke exposure in cigarettes with different tar content using filter analysis

    BITO R.; MINAMI N.; KAKEHI A.; YUKI D.; ONOZAWA M.
    Japan Tobacco Inc., R&D Group, Product Science Division, Yokohama, Kanagawa, Japan
    Filter analysis for evaluating the mouth level exposure (MLE) of smokers is non-invasive, allowing ordinary smoking behaviour with simple sample collection. We investigated 1) estimated MLEs to 36 smoke constituents using filter analysis, 2) MLEs of ...